Eur Rev Med Pharmacol Sci 2023; 27 (18): 8850-8859
DOI: 10.26355/eurrev_202309_33805

The role of opicapone in the management of Parkinson’s disease: an Italian consensus through a combined Nominal Group Technique and Delphi approach

A. Antonini, P. Barone, P. Calabresi, L. Lopiano, F. Morgante, F.E. Pontieri, M. Sensi, F. Stocchi; on behalf of The Delphi Panel Working Group

Department of Neuroscience, Movement Disorders Unit, Study Center for Neurodegeneration (CESNE), University of Padova, Padua, Italy. fabrizio.stocchi@uniroma5.it


OBJECTIVE: Opicapone (OPC) is a third-generation peripheral catechol-O-methyl transferase inhibitor (COMT-i) approved as add-on therapy to levodopa/DOPA decarboxylase inhibitors (DDCI) combinations in Parkinson’s disease (PD) patients with end-of-dose motor fluctuations. While the OPC effectiveness on motor symptoms is well known, there is still uncertainty about the timing of introduction, the management of levodopa dose, and the efficacy on non-motor symptoms (NMS).

SUBJECTS AND METHODS: A group of PD experts participated in a consensus activity composed of the Nominal Group Technique (NGT) and the Delphi method to better define the role of OPC. A list of statements was defined with the NGT and voted on through an online Delphi process by a panel of 85 Italian clinicians.

RESULTS: 24 statements were selected for the Delphi voting. Most statements (n=15, 62%) reached a consensus. A wide agreement was reached about the efficacy of OPC in treating motor fluctuations, including early morning akinesia and nocturnal akinesia. The panel widely agreed about the effectiveness of OPC in early fluctuating patients. The long-lasting inhibitory effect of OPC was recognized as an advantage over other COMT-i, resulting in a single daily dose and greater ease of introduction into the levodopa therapeutic regimen.

CONCLUSIONS: The efficacy of OPC observed in the clinical trials for the management of PD patients with motor fluctuations is also experienced in clinical practice. The review of the current positioning of OPC from the late to early stages of the disease may represent an important step in the evolution of the PD therapeutic approach.

Free PDF Download

To cite this article

A. Antonini, P. Barone, P. Calabresi, L. Lopiano, F. Morgante, F.E. Pontieri, M. Sensi, F. Stocchi; on behalf of The Delphi Panel Working Group
The role of opicapone in the management of Parkinson’s disease: an Italian consensus through a combined Nominal Group Technique and Delphi approach

Eur Rev Med Pharmacol Sci
Year: 2023
Vol. 27 - N. 18
Pages: 8850-8859
DOI: 10.26355/eurrev_202309_33805